Characterization of pathogenic monoclonal autoantibodies derived from muscle-specific kinase myasthenia gravis patients

Characterization of pathogenic monoclonal autoantibodies derived from muscle-specific kinase myasthenia gravis patients

Myasthenia gravis (MG) is a chronic autoimmune disorder characterized by muscle weakness and caused by pathogenic autoantibodies that bind to membrane proteins at the neuromuscular junction. Most patients have autoantibodies against the acetylcholine receptor (AChR), but a subset of patients have au...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Takata, K, Stathopoulos, P, Cao, M, Mané-Damas, M, Fichtner, M, Benotti, E, Jacobson, L, Waters, P, Irani, S, Martinez-Martinez, P, Beeson, D, Losen, M, Vincent, A, Nowak, R, O'Connor, K
Format:	Journal article
Wydane:	American Society for Clinical Investigation 2019

Podobne zapisy

Diagnostic use of autoantibodies in myasthenia gravis.
od: Leite, M, i wsp.
Wydane: (2010)

Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapy
od: Miriam L. Fichtner, i wsp.
Wydane: (2022-10-01)

Silencing of Dok-7 in adult rat muscle increases susceptibility to passive transfer myasthenia gravis
od: Gomez, A, i wsp.
Wydane: (2016)

Myasthenia gravis complement activity is independent of autoantibody titer and disease severity.
od: Miriam L Fichtner, i wsp.
Wydane: (2022-01-01)

Myasthenia gravis complement activity is independent of autoantibody titer and disease severity
od: Miriam L. Fichtner, i wsp.
Wydane: (2022-01-01)

Collagen Q - A potential target for autoantibodies in myasthenia gravis.
od: Zoltowska Katarzyna, M, i wsp.
Wydane: (2015)

The search for new antigenic targets in myasthenia gravis.
od: Cossins, J, i wsp.
Wydane: (2012)

Autoantibodies to agrin in myasthenia gravis patients.
od: Bin Zhang, i wsp.
Wydane: (2014-01-01)

Autoantibodies against neurologic antigens in nonneurologic autoimmunity
od: Stathopoulos, P, i wsp.
Wydane: (2019)

Antibodies identified by cell-based assays in myasthenia gravis and associated diseases.
od: Vincent, A, i wsp.
Wydane: (2012)

Characterization of an anti-fetal AChR monoclonal antibody isolated from a myasthenia gravis patient
od: Saxena, A, i wsp.
Wydane: (2017)

Autoantibodies in thymoma-associated myasthenia gravis with myositis or neuromyotonia.
od: Mygland, A, i wsp.
Wydane: (2000)

Autoantibodies in myasthenia gravis: cluster analysis and clinical correlations
od: Xupeng Sun, i wsp.
Wydane: (2025-02-01)

Myasthenia Gravis: Pathogenic Effects of Autoantibodies on Neuromuscular Architecture
od: Inga Koneczny, i wsp.
Wydane: (2019-07-01)

Clinical and pathophysiologic relevance of autoantibodies in neonatal myasthenia gravis
od: Shigeo Iijima
Wydane: (2021-11-01)

Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology
od: Miriam L. Fichtner, i wsp.
Wydane: (2020-05-01)

Overexpression of rapsyn in rat muscle increases acetylcholine receptor levels in chronic experimental autoimmune myasthenia gravis.
od: Martínez-Martínez, P, i wsp.
Wydane: (2007)

PATHOGENIC MECHANISMS UNDERLYING MYASTHENIA GRAVIS ASSOCIATED WITH MUSK ANTIBODIES
od: Viegas, S, i wsp.
Wydane: (2009)

Clinical value of cell-based assays in the characterisation of seronegative myasthenia gravis
od: Damato, V, i wsp.
Wydane: (2022)

Myasthenia gravis seronegative for acetylcholine receptor antibodies in South Korea: Autoantibody profiles and clinical features
od: Park, K, i wsp.
Wydane: (2018)

Guidelines for pre-clinical animal and cellular models of MuSK-myasthenia gravis.
od: Phillips, W, i wsp.
Wydane: (2015)

Antibodies in myasthenia gravis and related disorders.
od: Vincent, A, i wsp.
Wydane: (2003)

Autoantibodies in different forms of myasthenia gravis and in the Lambert-Eaton syndrome.
od: Vincent, A
Wydane: (2008)

Detection and clinical significance of serum autoantibodies in patients with myasthenia gravis
od: Yun LIU, i wsp.
Wydane: (2016-10-01)

Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics
od: Konstantinos Lazaridis, i wsp.
Wydane: (2020-02-01)

Myasthenia gravis.
od: Vincent, A, i wsp.
Wydane: (2004)

A retrospective multicenter study on clinical and serological parameters in patients with MuSK myasthenia gravis with and without general immunosuppression
od: Koneczny, I, i wsp.
Wydane: (2024)

Myasthenia gravis: diagnostic and management dilemmas.
od: Palace, J, i wsp.
Wydane: (2001)

Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis.
od: Losen, M, i wsp.
Wydane: (2005)

Compromised fidelity of B-cell tolerance checkpoints in AChR and MuSK myasthenia gravis
od: Lee, J, i wsp.
Wydane: (2016)

Myasthenia gravis
od: Massey Janice M, i wsp.
Wydane: (2007-11-01)

Antibodies to AChRs in seronegative myasthenia gravis
od: Leite, M, i wsp.
Wydane: (2006)

Scenarios for autoimmunization of T and B cells in myasthenia gravis.
od: Shiono, H, i wsp.
Wydane: (2003)

Myasthenia Gravis and Pregnancy
od: Papish M., i wsp.
Wydane: (2018-12-01)

SERONEGATIVE MYASTHENIA GRAVIS-CLINICAL/SEROLOGICAL ASPECTS
od: Huda, S, i wsp.
Wydane: (2014)

Thymoma and paraneoplastic myasthenia gravis.
od: Marx, A, i wsp.
Wydane: (2010)

Neuromyotonia in thymoma-associated myasthenia gravis: a clinico-serological study
od: Gastaldi, M, i wsp.
Wydane: (2018)

Serological and experimental studies in different forms of myasthenia gravis
od: Vincent, A, i wsp.
Wydane: (2018)

Seronegative myasthenia gravis.
od: Vincent, A, i wsp.
Wydane: (2004)

Myasthenia gravis.
od: Vincent, A, i wsp.
Wydane: (2001)